<?xml version='1.0' encoding='utf-8'?>
<document id="24550342"><sentence text="Intracellular effects of the Hepatitis C virus nucleoside polymerase inhibitor RO5855 (Mericitabine Parent) and Ribavirin in combination."><entity charOffset="87-99" id="DDI-PubMed.24550342.s1.e0" text="Mericitabine" /><entity charOffset="112-121" id="DDI-PubMed.24550342.s1.e1" text="Ribavirin" /><pair ddi="false" e1="DDI-PubMed.24550342.s1.e0" e2="DDI-PubMed.24550342.s1.e0" /><pair ddi="false" e1="DDI-PubMed.24550342.s1.e0" e2="DDI-PubMed.24550342.s1.e1" /></sentence><sentence text="Mericitabine (RG7128) is the prodrug of a highly selective cytidine nucleoside analog inhibitor (RO5855) of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase"><entity charOffset="0-12" id="DDI-PubMed.24550342.s2.e0" text="Mericitabine" /><entity charOffset="14-20" id="DDI-PubMed.24550342.s2.e1" text="RG7128" /><pair ddi="false" e1="DDI-PubMed.24550342.s2.e0" e2="DDI-PubMed.24550342.s2.e0" /><pair ddi="false" e1="DDI-PubMed.24550342.s2.e0" e2="DDI-PubMed.24550342.s2.e1" /></sentence><sentence text=" This study evaluated the effects of combining RO5855 and ribavirin on HCV replication in the HCV subgenomic replicon by using two drug-drug interaction models"><entity charOffset="47-53" id="DDI-PubMed.24550342.s3.e0" text="RO5855" /><entity charOffset="58-67" id="DDI-PubMed.24550342.s3.e1" text="ribavirin" /><pair ddi="false" e1="DDI-PubMed.24550342.s3.e0" e2="DDI-PubMed.24550342.s3.e0" /><pair ddi="false" e1="DDI-PubMed.24550342.s3.e0" e2="DDI-PubMed.24550342.s3.e1" /></sentence><sentence text=" The effects of RO5855 and ribavirin on the intracellular metabolism of each compound, on interferon-stimulated gene (ISG) expression, and on the viability of hepatocyte-derived cells were also investigated"><entity charOffset="16-22" id="DDI-PubMed.24550342.s4.e0" text="RO5855" /><entity charOffset="27-36" id="DDI-PubMed.24550342.s4.e1" text="ribavirin" /><pair ddi="false" e1="DDI-PubMed.24550342.s4.e0" e2="DDI-PubMed.24550342.s4.e0" /><pair ddi="false" e1="DDI-PubMed.24550342.s4.e0" e2="DDI-PubMed.24550342.s4.e1" /></sentence><sentence text=" RO5855 and ribavirin had additive inhibitory activities against HCV subgenomic replicon replication in drug-drug interaction analyses"><entity charOffset="1-7" id="DDI-PubMed.24550342.s5.e0" text="RO5855" /><entity charOffset="12-21" id="DDI-PubMed.24550342.s5.e1" text="ribavirin" /><pair ddi="false" e1="DDI-PubMed.24550342.s5.e0" e2="DDI-PubMed.24550342.s5.e0" /><pair ddi="false" e1="DDI-PubMed.24550342.s5.e0" e2="DDI-PubMed.24550342.s5.e1" /></sentence><sentence text=" RO5855 did not affect the uptake or phosphorylation of ribavirin in primary human hepatocytes, human peripheral blood mononuclear cells, or genotype 1b (G1b) replicon cells"><entity charOffset="56-65" id="DDI-PubMed.24550342.s6.e0" text="ribavirin" /></sentence><sentence text=" Similarly, ribavirin did not affect the concentrations of intracellular species derived from RO5855 in primary human hepatocytes or the formation of the triphosphorylated metabolites of RO5855"><entity charOffset="12-21" id="DDI-PubMed.24550342.s7.e0" text="ribavirin" /></sentence><sentence text=" Ribavirin at concentrations of &gt;40 Î¼M significantly reduced the viability of primary hepatocytes but not of Huh7, the G1b replicon, or interferon-cured Huh7 cells"><entity charOffset="1-10" id="DDI-PubMed.24550342.s8.e0" text="Ribavirin" /></sentence><sentence text=" RO5855 alone or with ribavirin did not significantly alter the viability of Huh7 or G1b replicon cells, and it did not significantly affect the viability of primary hepatocytes when it was administered alone"><entity charOffset="22-31" id="DDI-PubMed.24550342.s9.e0" text="ribavirin" /></sentence><sentence text=" The viability of primary hepatocytes was reduced when they were incubated with RO5855 and ribavirin, similar to the effects of ribavirin alone"><entity charOffset="80-86" id="DDI-PubMed.24550342.s10.e0" text="RO5855" /><entity charOffset="91-100" id="DDI-PubMed.24550342.s10.e1" text="ribavirin" /><entity charOffset="128-137" id="DDI-PubMed.24550342.s10.e2" text="ribavirin" /><pair ddi="false" e1="DDI-PubMed.24550342.s10.e0" e2="DDI-PubMed.24550342.s10.e0" /><pair ddi="false" e1="DDI-PubMed.24550342.s10.e0" e2="DDI-PubMed.24550342.s10.e1" /><pair ddi="false" e1="DDI-PubMed.24550342.s10.e0" e2="DDI-PubMed.24550342.s10.e2" /><pair ddi="false" e1="DDI-PubMed.24550342.s10.e1" e2="DDI-PubMed.24550342.s10.e1" /><pair ddi="false" e1="DDI-PubMed.24550342.s10.e1" e2="DDI-PubMed.24550342.s10.e2" /></sentence><sentence text=" RO5855 alone or with ribavirin had no effect on ISG mRNA levels in any of the cells tested"><entity charOffset="22-31" id="DDI-PubMed.24550342.s11.e0" text="ribavirin" /></sentence><sentence text=" In conclusion, RO5855 did not show any unfavorable interactions with ribavirin in human hepatocytes or an HCV subgenomic replicon system"><entity charOffset="70-79" id="DDI-PubMed.24550342.s12.e0" text="ribavirin" /></sentence><sentence text=" " /></document>